ReCode Therapeutics gets $80M to deliver on new RNA therapies for the lungs


ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.

Leave a Reply